Safety and Efficacy of Intratumoural Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open Phase 1 Trial
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2014
At a glance
- Drugs BA 015 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 07 Jan 2013 Planned end date changed from 1 Sep 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 07 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 01 Oct 2012 Results were reported at the 37th Congress of the European Society of Medical Oncology (ESMO-2012), according to a BioAlliance Pharma media release.